ERBB2 and triple-negative breast carcinoma: MDK overexpression is observed across all major breast cancer subtypes, including estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-positive, and triple-negative breast cancer (TNBC) [129].